Andy Beck

About Andy Beck

Pathology sits at the core of virtually every major medical decision — from the initial diagnosis of cancer to selecting targeted treatments and confirming the success of new therapies. It provides what no other specialty can: the ground truth. As healthcare enters a new era defined by precision medicine and data-driven decision-making, pathology isn’t just essential — it’s transformative.

Yet for too long, the field has operated behind the scenes. That must change. To realize the full potential of modern medicine, we must reposition pathology as its driving force.

At PathAI, the company I co-founded and lead as CEO, our mission is to improve patient outcomes with AI-powered pathology. We’ve built one of the world’s most advanced platforms for AI-powered digital pathology — combining deep learning with expertly curated annotations to deliver diagnostic insights that are faster, more accurate, and more reproducible than what is possible via manual slide review. By collaborating with leading biopharma companies, diagnostic labs, and academic centers, we ensure that our models don’t just work in theory — they deliver real-world clinical value. In fact, AISight Dx, our cloud-native digital pathology platform designed to maximize efficiency in anatomic pathology workflows, recently received 510(k) clearance from the FDA for use in primary diagnosis in clinical settings.

Raising the profile of pathology is integral to everything we do. PathAI has invested in technology that integrates seamlessly into existing digital pathology workflows, placing powerful AI tools directly in the hands of pathologists — not as replacements, but as partners in decision-making. We’ve published extensively in top-tier journals and presented at major scientific and medical conferences to elevate the visibility and credibility of AI in pathology.

Beyond technology and publications, we’ve worked closely with industry and academic leaders to demonstrate how pathology is central to some of the most important innovations in medicine today — from biomarker development and patient stratification to the acceleration of clinical trials. By embedding pathology into the earliest stages of therapeutic discovery and validation, we’re helping redefine its role from diagnostic endpoint to strategic enabler.

Recently, we launched Precision Pathology Network (PPN), a first-of-its-kind network of digital anatomic pathology laboratories powered by our AISight platform. PPN is designed to expand access to our latest AI-powered digital pathology products, unlock real-world data value, and fuel collaborative research with biopharma across a broad network of labs. This will enable participating laboratories to monetize real-world pathology data, support biopharma sponsored evidence generation studies and enable novel clinical development strategies.

The future of medicine depends on getting the right answers, at the right time, for the right patients. No field is better equipped to deliver that clarity than digital pathology. But recognition must catch up to reality. Through innovation, partnership, and a commitment to excellence, I am proud to help lead that shift in my role as CEO of PathAI.